Objective: We evaluated the prevalence of aspirin resistance and predictive factors for aspirin resistance in Korean type 2 diabetes patients. Approach and results: A total of 1045 type 2 diabetes patients from 11 hospitals who were taking aspirin (100mg/day for ≥2 weeks) and no other antiplatelet agents were studied to evaluate aspirin resistance. Aspirin resistance was measured in aspirin reaction units using VerifyNow®. Aspirin resistance was defined as ≥550 aspirin reaction units.Aspirin resistance was detected in 102 of the 1045 subjects (prevalence 9.8%). Aspirin resistance was associated with total cholesterol (P=0.013), LDL-cholesterol (P=0.028), and non-HDL cholesterol (P=0.008) concentrations in univariate analysis. In multivariate logistic regression analysis, only non-HDL cholesterol was associated with aspirin resistance in obese (BMI >25kg/m2) type 2 diabetes patients (adjusted odds ratio 3.55, 95% CI: 1.25-10.05, P=0.017). Conclusions: The prevalence of aspirin resistance in Korean type 2 diabetes patients is 9.8%. Non-HDL cholesterol is an independent risk factor for aspirin resistance, especially in obese type 2 diabetes patients.
|Number of pages||6|
|Publication status||Published - 2014 Jan 1|
- Aspirin resistance
- Atherogenic dyslipidemia
- Non-HDL cholesterol
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine